Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response

被引：0
|
作者：
Mai, Nicholas
Safonov, Anton
Marra, Antonio
Chen, Yuan
Chandarlapaty, Sarat
Razavi, Pedram
Plitas, George
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] European Inst Oncol IRCCS, Div Early Drug Dev, Milan, Italy
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1078
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
    Jenkins, Russell W.
    Thummalapalli, Rohit
    Carter, Jacob
    Canadas, Israel
    Barbie, David A.
    ANNUAL REVIEW OF MEDICINE, VOL 69, 2018, 69 : 333 - 347
  • [22] Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
    Nassar, Amin H.
    Adib, Elio
    Alaiwi, Sarah Abou
    El Zarif, Talal
    Groha, Stefan
    Akl, Elie W.
    Nuzzo, Pier Vitale
    Mouhieddine, Tarek H.
    Perea-Chamblee, Tomin
    Taraszka, Kodi
    El-Khoury, Habib
    Labban, Muhieddine
    Fong, Christopher
    Arora, Kanika S.
    Labaki, Chris
    Xu, Wenxin
    Sonpavde, Guru
    Haddad, Robert I.
    Mouw, Kent W.
    Giannakis, Marios
    Hodi, F. Stephen
    Zaitlen, Noah
    Schoenfeld, Adam J.
    Schultz, Nikolaus
    Berger, Michael F.
    MacConaill, Laura E.
    Ananda, Guruprasad
    Kwiatkowski, David J.
    Choueiri, Toni K.
    Schrag, Deborah
    Carrot-Zhang, Jian
    Gusev, Alexander
    CANCER CELL, 2022, 40 (10) : 1161 - +
  • [23] Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
    Pramod, Nikhil
    Makarov, Vladimir
    Dawsey, Scott
    Pavicic, Paul G.
    Patgunarajah, Ubenthira
    Nair, Monica
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Wee, Christopher Eing
    Nizam, Amanda
    Mian, Omar Y.
    Nguyen, Jane
    Diaz-Montero, C. Marcela
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 670 - 670
  • [24] Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors
    Smith, Katherine E. R.
    Markovic, Svetomir N.
    CLINICAL CHEMISTRY, 2024, 70 (01) : 25 - 26
  • [25] Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors
    Shinojima, Naoki
    Ozono, Kazutaka
    Yamamoto, Haruaki
    Abe, Sakiko
    Sasaki, Rumi
    Tomita, Yusuke
    Kai, Azusa
    Mori, Ryosuke
    Yamamoto, Takahiro
    Uekawa, Ken
    Matsui, Hirotaka
    Nosaka, Kisato
    Matsuzaki, Hiroaki
    Komohara, Yoshihiro
    Mikami, Yoshiki
    Mukasa, Akitake
    BRAIN TUMOR PATHOLOGY, 2023, 40 (03) : 185 - 190
  • [26] Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings
    Sturgill, Emma G.
    Misch, Amanda
    Jones, Carissa C.
    Luckett, Daniel
    Fu, Xiaotong
    Schlauch, Dan
    Jones, Suzanne F.
    Burris, Howard A., III
    Spigel, David R.
    McKenzie, Andrew J.
    ONCOLOGIST, 2022, 27 (03): : 175 - 182
  • [27] Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors
    Naoki Shinojima
    Kazutaka Ozono
    Haruaki Yamamoto
    Sakiko Abe
    Rumi Sasaki
    Yusuke Tomita
    Azusa Kai
    Ryosuke Mori
    Takahiro Yamamoto
    Ken Uekawa
    Hirotaka Matsui
    Kisato Nosaka
    Hiroaki Matsuzaki
    Yoshihiro Komohara
    Yoshiki Mikami
    Akitake Mukasa
    Brain Tumor Pathology, 2023, 40 : 185 - 190
  • [28] Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer
    Barroso-Sousa, Romualdo
    Jain, Esha
    Kim, Dewey
    Partridge, Ann H.
    Cohen, Ofir
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
    Tracy L. Rose
    William H. Weir
    Gregory M. Mayhew
    Yoichiro Shibata
    Patrick Eulitt
    Joshua M. Uronis
    Mi Zhou
    Matthew Nielsen
    Angela B. Smith
    Michael Woods
    Michele C. Hayward
    Ashley H. Salazar
    Matthew I. Milowsky
    Sara E. Wobker
    Katrina McGinty
    Michael V. Millburn
    Joel R. Eisner
    William Y. Kim
    British Journal of Cancer, 2021, 125 : 1251 - 1260
  • [30] Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
    Rose, Tracy L.
    Weir, William H.
    Mayhew, Gregory M.
    Shibata, Yoichiro
    Eulitt, Patrick
    Uronis, Joshua M.
    Zhou, Mi
    Nielsen, Matthew
    Smith, Angela B.
    Woods, Michael
    Hayward, Michele C.
    Salazar, Ashley H.
    Milowsky, Matthew I.
    Wobker, Sara E.
    McGinty, Katrina
    Millburn, Michael V.
    Eisner, Joel R.
    Kim, William Y.
    BRITISH JOURNAL OF CANCER, 2021, 125 (09) : 1251 - 1260
12345